The publication of this video was sponsored by Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany in Canada and the USA. This content is intended for healthcare professionals outside of the UK, Ireland, and the USA.
Prescribing information for avelumab is available here. Local prescribing conditions may vary. Please refer to prescribing information in your country of practice. Healthcare professionals are asked to report any suspected adverse reactions. Details on adverse event reporting are given at the end of this webpage.
This satellite symposium reviews current treatment strategies for locally advanced or metastatic urothelial carcinoma, combining clinical trial evidence, real-world data, shared decision-making principles, and emerging biomarker approaches to support personalised care in clinical practice.
Topics covered
- Evolving first-line treatment strategies and evidence from key Phase III trials
- Real-world effectiveness, safety profiles, and sequencing strategies following first-line therapy
- Shared decision-making frameworks and patient-centred care in Asian clinical settings
- Quality-of-life considerations and balancing efficacy with tolerability
- Biomarker development and future directions for treatment individualisation
Moderator
Syed Hussain1
Speaker
Marniza Saad2
Tetsuya Shindo3
Ravindran Kanesvaran4
1. University of Sheffield, UK
2. University of Malaysia, Kuala Lumpur
3. Sapporo Medical University, Japan
4. National Cancer Centre Singapore
| Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Merck Serono Limited – Tel: +44(0)20 8818 7373 or by email: [email protected] |
GL-AVE-00918
